Basic Information
| LncRNA/CircRNA Name | AB074169 |
| Synonyms | NA |
| Region | GRCh38_X:111124471-111127947 |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | papillary thyroid cancer |
| ICD-0-3 | NA |
| Methods | RNA-seq, Microarray, qPCR, Luciferase reporter assay, RIP etc. |
| Sample | papillary thyroid carcinoma tissues, cell lines (Nthy-ori3-1, TPC-1 and BCPAP) |
| Expression Pattern | down-regulated |
| Function Description | Here we conducted global lncRNA profiling and identified lncRNA AB074169 (lncAB) as significantly downregulated in PTC. Decreased expression of lncAB in PTC was caused by CpG hypermethylation within its gene promoter. Functional studies showed that lncAB overexpression led to cell cycle arrest and tumor growth inhibition in vitro and in vivo, whereas lncAB knockdown promoted cell proliferation. Mechanistic analyses revealed that lncAB bound KH-type splicing regulatory protein (KHSRP) and also decreased expression of KHSRP, thus increasing CDKN1a (p21) expression and decreasing CDK2 expression to repress cell proliferation. Taken together, these findings demonstrate that lncAB functions as a tumor suppressor during PTC tumorigenesis. |
| Pubmed ID | 29735546 |
| Year | 2018 |
| Title | Long noncoding RNA AB074169 inhibits cell proliferation via modulation of KHSRP-mediated p21 expression in papillary thyroid carcinoma. |
External Links
| Links for AB074169 | GenBank HGNC NONCODE |
| Links for papillary thyroid cancer | OMIM COSMIC |